MX2020004375A - Imipridonas para gliomas. - Google Patents

Imipridonas para gliomas.

Info

Publication number
MX2020004375A
MX2020004375A MX2020004375A MX2020004375A MX2020004375A MX 2020004375 A MX2020004375 A MX 2020004375A MX 2020004375 A MX2020004375 A MX 2020004375A MX 2020004375 A MX2020004375 A MX 2020004375A MX 2020004375 A MX2020004375 A MX 2020004375A
Authority
MX
Mexico
Prior art keywords
imipridone
administration
imipridones
subject
methods
Prior art date
Application number
MX2020004375A
Other languages
English (en)
Inventor
Martin Stogniew
Joshua E Allen
Varun Vijay Prabhu
Original Assignee
Oncoceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc
Publication of MX2020004375A publication Critical patent/MX2020004375A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Las imipridonas modulan selectivamente receptores de Clase A acoplados a proteínas G (GPCR), tales como la subfamilia de receptores de dopamina tipo D2, y son útiles para tratar afecciones y trastornos que necesitan dicha modulación, tales como los cánceres. Específicamente, el cáncer involucra una estructura de la línea media del cerebro, un cáncer que tiene una mutación en histona H3, o ambos. Además, se proporcionan métodos para identificar si es probable que un sujeto que tiene estas afecciones, sea sensible a un régimen de tratamiento, tal como la administración de imipridona. Además, también se proporcionan métodos para evaluar la eficacia de un régimen de tratamiento, tal como la administración de imipridona, monitorizar o proporcionar un pronóstico para un sujeto con esta afección.
MX2020004375A 2017-11-03 2018-11-05 Imipridonas para gliomas. MX2020004375A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581478P 2017-11-03 2017-11-03
US15/947,840 US10172862B2 (en) 2017-01-30 2018-04-08 Imipridones for gliomas
PCT/US2018/059209 WO2019090222A1 (en) 2017-11-03 2018-11-05 Imipridones for gliomas

Publications (1)

Publication Number Publication Date
MX2020004375A true MX2020004375A (es) 2020-11-11

Family

ID=63038820

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004375A MX2020004375A (es) 2017-11-03 2018-11-05 Imipridonas para gliomas.

Country Status (14)

Country Link
US (4) US10172862B2 (es)
EP (1) EP3703681A4 (es)
JP (2) JP7319989B2 (es)
KR (1) KR20200117979A (es)
CN (2) CN116173036A (es)
AU (1) AU2018360752A1 (es)
BR (1) BR112020008791A2 (es)
CA (1) CA3080815A1 (es)
EA (1) EA202090928A1 (es)
IL (1) IL274194A (es)
MA (1) MA50533A (es)
MX (1) MX2020004375A (es)
SG (1) SG11202003952YA (es)
WO (1) WO2019090222A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201806401YA (en) 2016-01-29 2018-08-30 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
WO2020172485A1 (en) * 2019-02-22 2020-08-27 Board Of Regents, The University Of Texas System Methods of using imipridones
JP2023536524A (ja) 2020-08-06 2023-08-25 エトヴェシュ ロラーンド トゥドマニュジェテム 新規イミプリドン誘導体の合成とその抗癌活性の評価
CN113248465B (zh) * 2021-06-16 2021-10-29 中国农业科学院北京畜牧兽医研究所 一种鹰嘴豆芽素a的合成方法
CN114632088B (zh) * 2022-05-16 2022-08-16 北京市神经外科研究所 阿糖胞苷化合物在制备治疗脊髓胶质瘤的药物中的用途
WO2024030645A1 (en) * 2022-08-05 2024-02-08 Chimerix, Inc. Pharmaceutical compositions and uses thereof for the treatment of glioma
CN117731654B (zh) * 2024-02-18 2024-05-07 首都医科大学附属北京天坛医院 Jjh201601在初发性脑胶质瘤和复发性脑胶质瘤治疗中的新用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1638178A (en) * 1924-11-04 1927-08-09 Union Switch & Signal Co Railway-traffic-controlling apparatus
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
WO2004082570A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
AU2004258147B2 (en) 2003-07-08 2009-04-30 State Of Queensland Acting Through Queensland Health Genetic marker of response to atypical antipsychotics and antidepressants and methods for use thereof
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
US8463365B2 (en) * 2007-09-19 2013-06-11 Oncofluor, Inc. Method for imaging and treating organs and tissues
WO2011160206A1 (en) * 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
US20130331381A1 (en) 2011-02-28 2013-12-12 Mcmaster University Treatment of Cancer WIth Dopamine Receptor Antagonists
JP6132833B2 (ja) 2011-04-29 2017-05-24 ザ ペン ステイト リサーチ ファンデーション 抗癌療法としての正常細胞および腫瘍細胞の小分子ｔｒａｉｌ遺伝子誘導
US9688679B2 (en) * 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
WO2014160130A1 (en) * 2013-03-13 2014-10-02 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
DK3546461T3 (da) * 2013-11-15 2021-09-13 Oncoceutics Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy
JP6756435B2 (ja) 2014-03-31 2020-09-16 ザ スクリプス リサーチ インスティテュート Ｔｒａｉｌ誘導のためのファーマコフォア
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
SG11201806401YA (en) * 2016-01-29 2018-08-30 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Also Published As

Publication number Publication date
IL274194A (en) 2020-06-30
CN111818919A (zh) 2020-10-23
EP3703681A4 (en) 2021-08-11
US10369154B2 (en) 2019-08-06
US20190183895A1 (en) 2019-06-20
US20200022982A1 (en) 2020-01-23
SG11202003952YA (en) 2020-05-28
JP2023139152A (ja) 2023-10-03
US10172862B2 (en) 2019-01-08
AU2018360752A1 (en) 2020-05-21
MA50533A (fr) 2020-09-09
JP7319989B2 (ja) 2023-08-02
CN116173036A (zh) 2023-05-30
US20210236499A1 (en) 2021-08-05
JP2021502417A (ja) 2021-01-28
EA202090928A1 (ru) 2020-08-14
BR112020008791A2 (pt) 2020-10-20
KR20200117979A (ko) 2020-10-14
US20180221375A1 (en) 2018-08-09
WO2019090222A1 (en) 2019-05-09
US10946022B2 (en) 2021-03-16
EP3703681A1 (en) 2020-09-09
CA3080815A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
MX2020004375A (es) Imipridonas para gliomas.
MX2023004443A (es) Modulacion del receptor acoplado a proteina g (gpcr) por imipridones.
CL2019002314A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
SG11202102208WA (en) Aryl hydrocarbon receptor antagonists and methods of use
GT201400275A (es) Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huèrfano rory
GT201500317A (es) Composiciones y métodos para alterar la señalizacion del segundo mensajero
CL2017001288A1 (es) Agonistas parciales del receptor de insulina
CL2019002108A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
UY37269A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
CR20150022A (es) Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno
CL2019002112A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
IL274179A (en) Targeted replacement of endogenous T cell receptors
DOP2015000227A (es) Virus de la enfermedad de newcastle y usos de los mismos
CL2014001993A1 (es) Uso de melatonina para el tratamiento de trastornos del ritmo circadiano
CO2017013041A2 (es) Método para tratar tumores neuroendocrinos donde se sobreexpresan receptores de somatostatatina
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
DK3319963T3 (da) Substituerede 4-azaindoler og deres anvendelse som glun2b receptormodulatorer
CR20140424A (es) Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio
CR20150140A (es) Antiandrógenos para el tratamiento del cáncer de prostata resistente a la castración metastásico
CO2017004074A2 (es) Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
CR20150483A (es) Composiciones y métodos para el diagnóstico y tratamiento del cáncer hepático
MX2018004289A (es) Receptores de antigenos quimericos dirigidos a psca.
AR106133A1 (es) Métodos para el tratamiento de la epilepsia
CL2016001739A1 (es) Trece compuestos específicos derivados de 6,7,8,8a-tetrahidro-5h-imidazol1,5-a-piridin-1,3-diona, moduladores alostéricos positivos map del receptor metabotrópico del glutamato 4 mglur4 composiciones farmacológicas procedimiento de preparación útiles para el tratamiento del parkinson, ansiedad, emesis, trastorno obsesivo-compulsivo, autismo, neuroprotección, cáncer, depresión, esquizofrenia y diabetes tipo 2.
AR101296A1 (es) Métodos y aparatos para evaluar las condiciones de fondo de pozo a través de detección de fluido